GLP-1 Drugs, PCOS, and Stopping Treatment

A post on r/peptides this month described a pattern that shows up often in PCOS-adjacent corners of peptide forums: months of weight loss on Wegovy (semaglutide), polycystic ovary syndrome (PCOS) symptoms that eased alongside it, a return of those symptoms after stopping, and a move to the investigational peptide retatrutide, which the community shorthand "Rta" usually refers to, with a question about whether to keep injecting weekly or stretch to once a month^[6]. That second question does not have a published answer. Every trial that established how well semaglutide and retatrutide work tested a fixed weekly schedule^[1][3], and semaglutide's regulatory approval does not list PCOS as an indication at all^[5].

Why PCOS symptoms often ease, then return

Semaglutide is not approved to treat PCOS in the EU, UK, or US. It is approved for chronic weight management and for type-2 diabetes^[5]. PCOS is closely tied to insulin resistance and excess weight in many patients, so a drug that lowers weight and improves insulin sensitivity can ease PCOS symptoms as a side effect of treating the underlying weight and metabolic picture, even without a PCOS-specific label.

A 2026 systematic review pooled 11 randomized controlled trials of GLP-1 receptor agonists in women with PCOS and reported a mean reduction in body mass index of 1.38 kg/m2 compared with control groups^[2]. The reviewers rated that evidence as low certainty and said the data on metabolic, reproductive, and psychological outcomes remain too limited to draw firm conclusions. That is the honest state of the evidence: a real signal, on thin proof.

The review's authors searched thousands of records and kept only 11 trials because most published work on GLP-1 drugs and PCOS is small, short, or not randomized. That gap matters for anyone reading a forum post as evidence. A person describing their own PCOS symptoms improving on semaglutide is reporting something plausible and consistent with the mechanism, but one account is not a trial, and the trials that exist are underpowered to say how large or durable the reproductive benefit is.

What happens when the drug stops

STEP 4, the trial most relevant to the pattern the Reddit poster described, randomized 803 adults who had already lost weight on semaglutide for 20 weeks to either keep taking the drug or switch to placebo^[1]. Over the following 48 weeks, the group that stayed on semaglutide lost an additional 7.9% of body weight. The group switched to placebo regained 6.9%, a difference of 14.8 percentage points between the two arms. The trial measured body weight, not PCOS symptoms directly, but the pattern lines up with what the forum post described: the effect tracks the drug, and it fades once the drug stops.

The retatrutide numbers behind the appeal

Retatrutide activates three receptors at once, GLP-1, GIP, and glucagon, instead of the single GLP-1 receptor semaglutide targets. In the Phase 2 obesity trial, the group given the highest weekly dose, 12 mg, lost a mean 24.2% of body weight at 48 weeks, against 2.1% on placebo^[3]. That is a larger effect than anything published for semaglutide, which is part of why retatrutide shows up in posts from people who have plateaued or regained weight on an approved GLP-1 drug. It is also why real-world use of the peptide is running well ahead of its regulatory file.

What this is not

This is not a recommendation to switch drugs, stretch a dosing interval, or self-manage PCOS symptoms with an unapproved peptide. Retatrutide has no marketing authorization from the FDA, the EMA, or any national regulator PeptideMethods tracks^[3][4]. The published human data comes from Phase 2 trials that ran for 48 weeks or less, with a few hundred participants each. Nobody has published a trial testing monthly retatrutide dosing, so a person who cuts injections from weekly to monthly is running an untested change on their own body, not following a studied protocol.

The FDA has also said plainly that retatrutide cannot legally be compounded under federal law, and the agency has issued warning letters to companies selling it anyway. As of the most recent tally, the FDA had logged roughly 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide^[4], a reminder that an unregulated supply chain carries its own risk, separate from the risk of the molecule itself.

What this means

If PCOS symptoms return after stopping a GLP-1 drug, that is consistent with how these medications appear to work: the benefit tracks continued use rather than resetting the underlying condition, at least based on the semaglutide data available today^[1]. Decisions about restarting treatment, switching to a different drug, or changing how often to inject belong with a clinician who can weigh the diagnosis, the drug's approval status, and the gaps in the safety data. A prescriber managing PCOS with semaglutide is working from an approved product with a large trial base behind it, even used off-label. A person sourcing retatrutide outside a clinical trial is not.

None of this settles the underlying question the forum poster asked, whether to inject weekly or monthly. It shows why nobody, including PeptideMethods, can answer it from the published record. Weekly is what every relevant trial tested. Monthly is untested territory, and untested territory is exactly where a clinician's judgment about an individual case matters more than a community consensus built from scattered self-reports.